WuXi AppTec Co., Ltd. Class A 603259
SSE · China · Health Technology
CNY 167.34+6.68 (+4.16%)
Market closed· · CNY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · CNY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Investing.com -- Bernstein has identified several China-based biopharmaceutical companies positioned to benefit from evolving drug development capabilities, with a focus on integrated platforms and service providers that support AI-enabled research and development workflows.
Stricter quality rules, complex biologics and outsourcing are driving demand for impurity isolation, synthesis and analytics, creating opportunities for specialized labs and CROs.Dublin, Sept. 29, 2026 (GLOBE NEWSWIRE) -- "Pharmaceutical Impurity Synthesis and Isolation Services - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global pharmaceutical impurity synthesis and isolation services market was valued at US$1.3 billion in 2024 and is projected to
Opportunities center on AI-enabled decentralized trials, therapeutic specialization, global patient recruitment, regulatory support, real-world evidence and integrated partnerships.Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- "Contract Research Organization Services Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. The Contract Research Organization Services Market research report provides strategic analysis of a sector projected to reach USD 87.43 billion in
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.